Abstract
The title compound, (+)-14,14-difluoro-4-demethoxydaunorubicin hydrochloride (9), was prepared starting from the readily available (−)-hydroxy ester (10). This synthesis featured the efficient synthetic route to (−)-14,14-difluoro-4-demethoxy-7-deoxydaunomycinone (20) employing the Reformatsky reaction of ethyl bromodifluoroacetate with the (−)-siloxy aldehyde (14) and previously developed glycosylation method in which trimethylsilyl trifluoromethanesulfonate was used as an activator. In P388 in vitro test, 9 was found to be fifty times more active than adriamycin (1). Prominent antitumor activity was also observed for 9 in P388 in vivo test.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
